Abstract:Advances in manufacturing technology coupled with the increased potency of new biotherapeutic modalities have created an external environment where continuous manufacturing (CM) can address a growing need. Amgen has successfully implemented a hybrid CM process for a commercial lifecycle program. In this process, the bioreactor, harvest, capture column, and viral inactivation/depth filtration unit operations were integrated together in an automated, continuous module, while the remaining downstream unit operations took place in stand‐alone batch mode. CM operations are particularly suited for so‐called "high mix, low volume" manufacturing plants, where a variety of molecules are manufactured in relatively low volumes. The selected molecule fit this mold and was manufactured in a low‐capital micro‐footprint suite attached to an existing therapeutic production facility. Use of a hybrid process within an already operating facility required less capital and minimized complexity. To enable this hybrid CM process, an established fed‐batch process was converted to a perfusion process with continuous harvest. Development efforts included both process changes and the generation of a novel cell line adapted to long‐term perfusion. Chromatography resins were updated, and purification processes adapted to handle variable inputs due to the fluctuations in harvest titer from the lengthy production process. A novel automated single‐use (SU) viral inactivation (VI) skid was introduced, which entailed the development of a robust pH verification and alarm system, along with procedures for product isolation to allow discard of specific cycles. The CM process demonstrated consistent performance, meaning it met predefined performance criteria (including product quality attributes, or PQAs) when operated within established process parameters and manufactured according to applicable procedures. Using a 75% reduction in scale, it resulted in a five‐fold reduction in process media and buffer usage, a fifteen‐fold increase in mass per thaw, and an overall process productivity increase of 45‐fold (as measured by grams drug substance per liter per day.) The hybrid CM process also enabled increased material demand to be met with no change in cost of goods manufactured or plant capacity, due to the repurposing of existing facility space and the flexible duration of the hybrid CM harvest. Overall, the success of the hybrid CM platform represents an exciting opportunity to reduce costs and increase process efficiency in industry.

Upstream process intensification and continuous manufacturing

Converting a Mab Downstream Process from Batch to Continuous Using Process Modeling and Process Analytical Technology.

Model-assisted Approaches for Continuous Chromatography: Current Situation and Challenges.

Model-assisted process development, characterization and design of continuous chromatography for antibody separation

Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study

From Chemostats to High-Density Perfusion: the Progression of Continuous Mammalian Cell Cultivation

Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications

Integrated continuous production of recombinant therapeutic proteins

Toward microfluidic continuous-flow and intelligent downstream processing of biopharmaceuticals

Modeling and techno-economic analysis of downstream manufacturing process intensification strategies for existing biopharmaceutical facilities

Pre-stage perfusion and ultra-high seeding cell density in CHO fed-batch culture: a case study for process intensification guided by systems biotechnology

Process Design of a Fully Integrated Continuous Biopharmaceutical Process using Economic and Ecological Impact Assessment

Reviewing the process intensification landscape through the introduction of a novel, multitiered classification for downstream processing

Process performance and product quality in an integrated continuous antibody production process

Developing the biofacility of the future based on continuous processing and single-use technology

1H NMR-based Process Understanding and Biochemical Marker Identification Methodology for Monitoring CHO Cell Culture Process During Commercial-Scale Manufacturing

Progress in fed-batch culture for recombinant protein production in CHO cells

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Continuous Manufacturing of Active Pharmaceutical Ingredients: Current Trends and Perspectives

Stepwise Cell Culture Process Intensification for High-productivity and Cost-effective Commercial Manufacturing of a Mabcalin TM Bispecifics

GMP implementation of a hybrid continuous manufacturing process for a recombinant non‐mAb protein—A case study